Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18575715rdf:typepubmed:Citationlld:pubmed
pubmed-article:18575715lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:18575715lifeskim:mentionsumls-concept:C0007099lld:lifeskim
pubmed-article:18575715lifeskim:mentionsumls-concept:C0235782lld:lifeskim
pubmed-article:18575715lifeskim:mentionsumls-concept:C0334227lld:lifeskim
pubmed-article:18575715lifeskim:mentionsumls-concept:C0005516lld:lifeskim
pubmed-article:18575715lifeskim:mentionsumls-concept:C0267892lld:lifeskim
pubmed-article:18575715lifeskim:mentionsumls-concept:C0171955lld:lifeskim
pubmed-article:18575715lifeskim:mentionsumls-concept:C1524075lld:lifeskim
pubmed-article:18575715lifeskim:mentionsumls-concept:C0439792lld:lifeskim
pubmed-article:18575715lifeskim:mentionsumls-concept:C0337112lld:lifeskim
pubmed-article:18575715pubmed:issue1lld:pubmed
pubmed-article:18575715pubmed:dateCreated2008-6-25lld:pubmed
pubmed-article:18575715pubmed:abstractTextGallbladder carcinoma (GC) is a relatively uncommon malignancy and is often caused by diagnostic difficulties in distinguishing the extension of carcinoma in situ (CIS) from invasive carcinoma along Rokitansky-Aschoff sinuses (RAS). The laminin-5, a heterotrimer, is composed of alpha-3, beta-3 and gamma-2 chains. The gamma-2 chain is expressed in various invasive carcinoma cells. There are numerous reports that have described that laminin-5-gamma-2 is associated with tissue invasion in many organs. However, few studies are found in gallbladder carcinoma. To clarify the relationship between laminin-5-gamma-2 chain (LN-5) expression and the development of GCs, we performed an immunohistochemical study of 93 GCs. Cases were classified into three groups: CIS with/without the extension along RAS (Group A; n=17), carcinoma invading mucosa or muscular layer (Group B; n=5) and carcinoma invading beyond perimuscular connective tissue (Group C; n=71). The immunohistochemical intracytoplasmic expression was detected in the invasive fronts of the tumor. In the invasive components of Group B and C, LN-5 was expressed in 100 and 97% of cases, respectively, whereas in the CIS lesions of GCs, expression was not observed in Group A. LN-5 expression in the GCs tended to increase as tumors developed, which may be an indicator of the potential invasiveness of the tumor. Our results indicate that, in GCs, a strong intracytoplasmic expression of LN-5 was identified in the cancer cells whether in situ they extend along RAS or invading stroma.lld:pubmed
pubmed-article:18575715pubmed:languageenglld:pubmed
pubmed-article:18575715pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18575715pubmed:citationSubsetIMlld:pubmed
pubmed-article:18575715pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18575715pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18575715pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18575715pubmed:statusMEDLINElld:pubmed
pubmed-article:18575715pubmed:monthJullld:pubmed
pubmed-article:18575715pubmed:issn1021-335Xlld:pubmed
pubmed-article:18575715pubmed:authorpubmed-author:TsuneyoshiMas...lld:pubmed
pubmed-article:18575715pubmed:authorpubmed-author:YaoTakashiTlld:pubmed
pubmed-article:18575715pubmed:authorpubmed-author:InoueTakahiro...lld:pubmed
pubmed-article:18575715pubmed:authorpubmed-author:YonemasuHirot...lld:pubmed
pubmed-article:18575715pubmed:authorpubmed-author:TanakaMasaoMlld:pubmed
pubmed-article:18575715pubmed:authorpubmed-author:YamaguchiHiro...lld:pubmed
pubmed-article:18575715pubmed:authorpubmed-author:FujiiKeiKlld:pubmed
pubmed-article:18575715pubmed:authorpubmed-author:EguchiTakashi...lld:pubmed
pubmed-article:18575715pubmed:authorpubmed-author:NishiyamaKen-...lld:pubmed
pubmed-article:18575715pubmed:issnTypePrintlld:pubmed
pubmed-article:18575715pubmed:volume20lld:pubmed
pubmed-article:18575715pubmed:ownerNLMlld:pubmed
pubmed-article:18575715pubmed:authorsCompleteYlld:pubmed
pubmed-article:18575715pubmed:pagination33-9lld:pubmed
pubmed-article:18575715pubmed:meshHeadingpubmed-meshheading:18575715...lld:pubmed
pubmed-article:18575715pubmed:meshHeadingpubmed-meshheading:18575715...lld:pubmed
pubmed-article:18575715pubmed:meshHeadingpubmed-meshheading:18575715...lld:pubmed
pubmed-article:18575715pubmed:meshHeadingpubmed-meshheading:18575715...lld:pubmed
pubmed-article:18575715pubmed:meshHeadingpubmed-meshheading:18575715...lld:pubmed
pubmed-article:18575715pubmed:meshHeadingpubmed-meshheading:18575715...lld:pubmed
pubmed-article:18575715pubmed:meshHeadingpubmed-meshheading:18575715...lld:pubmed
pubmed-article:18575715pubmed:meshHeadingpubmed-meshheading:18575715...lld:pubmed
pubmed-article:18575715pubmed:meshHeadingpubmed-meshheading:18575715...lld:pubmed
pubmed-article:18575715pubmed:meshHeadingpubmed-meshheading:18575715...lld:pubmed
pubmed-article:18575715pubmed:meshHeadingpubmed-meshheading:18575715...lld:pubmed
pubmed-article:18575715pubmed:year2008lld:pubmed
pubmed-article:18575715pubmed:articleTitleLaminin-5 (gamma2 chain) is a marker of invading cancer cells in human gallbladder carcinoma: special emphasis on extension of carcinoma in situ along Rokitansky-Aschoff sinuses.lld:pubmed
pubmed-article:18575715pubmed:affiliationKyushu Cancer Center, Fukuoka 811-1395, Japan. eguchi.t@hamanomachi.jplld:pubmed
pubmed-article:18575715pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18575715pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18575715lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18575715lld:pubmed